Dianthus Therapeutics DNTH Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Dianthus Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The official record: Dianthus Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Dianthus Therapeutics's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Dianthus Therapeutics's total liabilities?
- Dianthus Therapeutics (DNTH) reported total liabilities of $45.57M in Q1 2026.
- How has Dianthus Therapeutics's total liabilities changed year-over-year?
- Dianthus Therapeutics's total liabilities increased by 128.1% year-over-year, from $19.97M to $45.57M.
- What is the long-term trend for Dianthus Therapeutics's total liabilities?
- Over 5 years (2020 to 2025), Dianthus Therapeutics's total liabilities has grown at a 16.2% compound annual growth rate (CAGR), from $17.71M to $37.52M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.